
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics is in a prime position for growth with their current portfolio of FDA-approved products and their plans for expanding into new therapeutic areas, such as their novel NaV blocker technology. The launch of Zelsuvmi has shown early success, with already accelerating adoption and potential for significant revenue in the near future. With a low market cap and positive script trends, Pelthos Therapeutics has the potential for a significant valuation re-rating and positioning as a leading player in the biopharmaceutical industry.
Bears say
Pelthos Therapeutics is a relatively new biopharmaceutical company that has a narrow focus on the pediatric dermatology market. While they have three FDA-approved products, their pipeline is limited and they do not have a strong presence in other therapeutic areas. Additionally, their financials are concerning, with a need for additional capital and potential dilution for existing investors. Furthermore, there are significant risks associated with their products, including regulatory and clinical risks, which could significantly reduce their value and impact their potential for long-term success.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares